ArticleCirculation research2020
The A-to-I RNA Editing Enzyme
Article in Circulation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy.Journal of nanobiotechnology · 2026Article
- RNA editing in cardiovascular health and disease.Communications biology · 2026Review
- Charting and probing the activity of ADARs in human development and cell-fate specification.Nature communications · 2024Article
- Temporal landscape and translational regulation of A-to-I RNA editing in mouse retina development.BMC biology · 2024Article
- Epitranscriptomic Regulations in the Heart.Physiological research · 2024Review
- Posttranscriptional Regulation by Proteins and Noncoding RNAs.Advances in experimental medicine and biology · 2024Article
- RNA modification in cardiovascular disease: implications for therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Benchmarking RNA Editing Detection Tools.Biotech (Basel (Switzerland)) · 2023Review
- Integration of epigenetic regulatory mechanisms in heart failure.Basic research in cardiology · 2023Review
- RNA modifications in cardiovascular health and disease.Nature reviews. Cardiology · 2023Review
- RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease.Cardiovascular drugs and therapy · 2023Review
- Adenosine deaminase acting on RNA 1 (ADAR1) as crucial regulators in cardiovascular diseases: structures, pathogenesis, and potential therapeutic approach.Frontiers in pharmacology · 2023Review
- Change of Heart: the Epitranscriptome of Small Non-coding RNAs in Heart Failure.Current heart failure reports · 2022Review
- Functions Beyond the Editor's I in Regulating Cardiac Innate Immunity and Heart Failure.Circulation research · 2022Article
- Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases.Molecular therapy. Nucleic acids · 2022Review
- Functional roles of epitranscriptomic marks in the cardiovascular system and disease: a narrative review.Annals of translational medicine · 2022Review
- ADAR1 RNA editing regulates endothelial cell functions via the MDA-5 RNA sensing signaling pathway.Life science alliance · 2022Article
- ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Epitranscriptomics of cardiovascular diseases (Review).International journal of molecular medicine · 2022Review
- Global RNA editing identification and characterization during human pluripotent-to-cardiomyocyte differentiation.Molecular therapy. Nucleic acids · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.